SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study

Katarzyna Karłowicz; Konrad Lewandowski; Edyta Tulewicz-Marti; Katarzyna Maciejewska; Adam Tworek; Beata Stępień-Wrochna; Martyna Głuszek-Osuch; Michał Łodyga; Grażyna Rydzewska

doi:10.5114/pg.2023.130126

Abstract

2/2024 vol. 19

Original paper

SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study

Katarzyna Karłowicz ¹

,

Konrad Lewandowski ¹

,

Edyta Tulewicz-Marti ¹

,

Katarzyna Maciejewska ¹

,

Adam Tworek ¹

,

Beata Stępień-Wrochna ¹

,

Martyna Głuszek-Osuch ^{1, 2}

,

Michał Łodyga ^{1, 2}

,

Grażyna Rydzewska ^{1, 3}

Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
Department of Internal Medicine, Faculty of Health Science, Medical University of Warsaw, Warsaw, Poland
Collegium Medicum, Jan Kochanowski University, Kielce, Poland

Gastroenterology Rev 2024; 19 (2): 198–205

DOI: https://doi.org/10.5114/pg.2023.130126

Online publish date: 2023/07/27

View full text

AMA

Karłowicz K, Lewandowski K, Tulewicz-Marti E, et al. SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study. Gastroenterology Review/Przegląd Gastroenterologiczny. 2024;19(2):198-205. doi:10.5114/pg.2023.130126.

APA

Karłowicz, K., Lewandowski, K., Tulewicz-Marti, E., Maciejewska, K., Tworek, A., & Stępień-Wrochna, B. et al. (2024). SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study. Gastroenterology Review/Przegląd Gastroenterologiczny, 19(2), 198-205. https://doi.org/10.5114/pg.2023.130126

Chicago

Karłowicz, Katarzyna, Konrad Lewandowski, Edyta Tulewicz-Marti, Katarzyna Maciejewska, Adam Tworek, Beata Stępień-Wrochna, and Martyna Głuszek-Osuch et al. 2024. "SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study". Gastroenterology Review/Przegląd Gastroenterologiczny 19 (2): 198-205. doi:10.5114/pg.2023.130126.

Harvard

Karłowicz, K., Lewandowski, K., Tulewicz-Marti, E., Maciejewska, K., Tworek, A., Stępień-Wrochna, B., Głuszek-Osuch, M., Łodyga, M., and Rydzewska, G. (2024). SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study. Gastroenterology Review/Przegląd Gastroenterologiczny, 19(2), pp.198-205. https://doi.org/10.5114/pg.2023.130126

MLA

Karłowicz, Katarzyna et al. "SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 19, no. 2, 2024, pp. 198-205. doi:10.5114/pg.2023.130126.

Vancouver

Karłowicz K, Lewandowski K, Tulewicz-Marti E, Maciejewska K, Tworek A, Stępień-Wrochna B et al. SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients – does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study. Gastroenterology Review/Przegląd Gastroenterologiczny. 2024;19(2):198-205. doi:10.5114/pg.2023.130126.

Introduction

Inflammatory bowel disease (IBD) patients use a wide variety of immunosuppressive drugs, including biologics, but their effect on SARS-CoV-2 vaccine antibody levels remains a mystery.

Aim

We analysed whether the drugs used in the treatment of IBD patients could affect the concentration of SARS-CoV-2 antibodies.

Material and methods

This is a prospective, single-centre evaluation of the persistence of SARS-CoV-2 antibodies after vaccination at various time points: every 2 months throughout the 6th month after the first dose.

Results

We included a total of 346 vaccinated IBD patients in the study. A negative correlation between antibody level and time from full vaccination was confirmed for the following types of therapy: infliximab (rho = –0.32, p < 0.001), adalimumab (rho = –0.35, p = 0.025), and vedolizumab (rho = –0.50, p < 0.001). In the case of other, long-term drug administration, a negative correlation between antibody level and time from full vaccination was confirmed for mesalazine (rho = –0.35, p < 0.001), budesonide (rho = –0.58, p = 0.004), systemic glucocorticoids (rho = –0.58, p < 0.001), and azathioprine (rho = –0.44, p < 0.001).

Conclusions

Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.